Lobbying firm

AVANIR PHARMACEUTICALS

Central Nervous System Pharmaceutical Research and Development/Pharmaceutical Sales

Filings
25
Clients
1
Total income
—
Lobbyists
3
Years active
2014–2022

Filings counts every document on the register, amendments included. Income is the fees reported to clients, counting the current version of each report once.

Income by year

Fees reported, $ thousands 2014 to 2022

Filings

25 filings, newest first.
Filing Client Income Expenses
4th Quarter - Termination
4th Quarter 2022
AVANIR PHARMACEUTICALS — income $40,000 expenses
3rd Quarter - Report
3rd Quarter 2022
AVANIR PHARMACEUTICALS — income $70,000 expenses
2nd Quarter - Report
2nd Quarter 2022
AVANIR PHARMACEUTICALS — income $90,000 expenses
1st Quarter - Report
1st Quarter 2022
AVANIR PHARMACEUTICALS — income $70,000 expenses
4th Quarter - Report
4th Quarter 2021
AVANIR PHARMACEUTICALS — income $70,000 expenses
3rd Quarter - Report
3rd Quarter 2021
AVANIR PHARMACEUTICALS — income $70,000 expenses
Registration - Amendment
3rd Quarter 2021
AVANIR PHARMACEUTICALS — income — expenses
4th Quarter - Termination Amendment (No Activity)
4th Quarter 2017, no activity
AVANIR PHARMACEUTICALS — income $60,000 expenses
4th Quarter - Terminationreplaced
4th Quarter 2017
AVANIR PHARMACEUTICALS — income $80,000 expenses
3rd Quarter - Report
3rd Quarter 2017
AVANIR PHARMACEUTICALS — income $80,000 expenses

Clients

Everyone this filer has reported for, with the reports filed and the income they disclose.

ClientReportsIncome
AVANIR PHARMACEUTICALS 19 —

Lobbyists

Everyone named on this filer's reports, with the government post they most recently disclosed here.

LobbyistCovered position, as disclosed
SARAH CHRISTINE D'ORSIE Director of Advocacy
CATHERINE DRATZ FERGUSON —
CRYSTAL LYNN VANUCH Head of Government Affairs

From reports filed under the Lobbying Disclosure Act. A firm reports income from each client; an organisation lobbying for itself reports its own expenses instead. Each figure links to the filing it comes from.